KIT and renal cell carcinoma: Pazopanib, an approved medication for handling renal cell carcinoma and soft tissue sarcoma, is a VEGF receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, and stem cell receptor c-Kit inhibitor [75]. The abovementioned drugs are relevant to the immune balance in other diseases and may benefit sepsis patients.